Sruthi Vellanki MD, MBA, FACP (@sruthivellankit) 's Twitter Profile
Sruthi Vellanki MD, MBA, FACP

@sruthivellankit

Passionate hem Onc hospitalist, loving wife to my handsome hubby, devoted daughter, and a bit of a mischievous sister. awaiting adventures in Hem onc# FamilyFun

ID: 1109158985901506561

calendar_today22-03-2019 18:24:44

34 Tweet

19 Takipçi

83 Takip Edilen

Nishanth Thalambedu (@nishant37943085) 's Twitter Profile Photo
Nishanth Thalambedu
@nishant37943085

a year ago

Excellent 🎊🎊🎊

UAMS Cancer (@uamscancer) 's Twitter Profile Photo
UAMS Cancer
@uamscancer

10 months ago

🙌🙌🙌UAMS is one of the 10 most viewed hematology and medical oncology residency programs out of 13,000! Well done, Kostas Arnaoutakis! ama-assn.org/medical-studen…

Sruthi Vellanki MD, MBA, FACP (@sruthivellankit) 's Twitter Profile Photo
Sruthi Vellanki MD, MBA, FACP
@sruthivellankit

10 months ago

Proud of my handsome hubby

Nishanth Thalambedu (@nishant37943085) 's Twitter Profile Photo
Nishanth Thalambedu
@nishant37943085

9 months ago

Good timing right before #ASH2024

Vincent Rajkumar (@vincentrk) 's Twitter Profile Photo
Vincent Rajkumar
@vincentrk

9 months ago

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.
Samer Al Hadidi, MD,MS,FACP (@hadidisamer) 's Twitter Profile Photo
Samer Al Hadidi, MD,MS,FACP
@hadidisamer

9 months ago

#ASH24 ASH #mmsm Available MM therapies in 2025

#ASH24 <a href="/ASH_hematology/">ASH</a> #mmsm Available MM therapies in 2025
𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM (@nihardesai89) 's Twitter Profile Photo
𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM
@nihardesai89

9 months ago

Previous trials tested hydroxyurea in patients with Hb SS but excluded patients with Hb SC! Dr. Adomakoh reports the results of the PIVOT trial testing hydroxyurea in patients with HB SC || #ASH24 plenary 🙌🏼 Results simultaneously published in NEJM evidence 💪🏼

Previous trials tested hydroxyurea in patients with Hb SS but excluded patients with Hb SC! Dr. Adomakoh reports the results of the PIVOT trial testing hydroxyurea in patients with HB SC || #ASH24 plenary 🙌🏼 Results simultaneously published in <a href="/NEJM/">NEJM</a> evidence 💪🏼
Samer Al Hadidi, MD,MS,FACP (@hadidisamer) 's Twitter Profile Photo
Samer Al Hadidi, MD,MS,FACP
@hadidisamer

9 months ago

#ASH24 #mmsm ASH Nice algorithm for therapeutic anticoagulation for cancer associated VTE

#ASH24 #mmsm <a href="/ASH_hematology/">ASH</a> Nice algorithm for therapeutic anticoagulation for cancer associated VTE
Asis Shrestha, MD, FACP (@asis_shr) 's Twitter Profile Photo
Asis Shrestha, MD, FACP
@asis_shr

9 months ago

UAMS team gathering at poster 3789 #ASH24 presented by Bhavesh Mohan Lal, MD Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma Samer Al Hadidi, MD,MS,FACP Anup Trikannad MD Sruthi Vellanki MD, MBA, FACP

UAMS team gathering at poster 3789 #ASH24 presented by <a href="/Dr_Bhavesh_M/">Bhavesh Mohan Lal, MD</a> Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma <a href="/HadidiSamer/">Samer Al Hadidi, MD,MS,FACP</a> <a href="/AnupTrix/">Anup Trikannad MD</a> <a href="/sruthivellankiT/">Sruthi Vellanki MD, MBA, FACP</a>